1: Blair HA. Befotertinib: First Approval. Drugs. 2023 Oct;83(15):1433-1437.
doi: 10.1007/s40265-023-01946-w. PMID: 37751131.
2: Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, Fang J, Chen G, Zhang Z, Lv D,
Jiang L, Wu R, Jin X, Zhang X, Zhang J, Xie C, Sun G, Huang D, Cui J, Guo R, Han
Z, Chen Z, Liang J, Zhuang W, Hu X, Zang A, Zhang Y, Cang S, Lan Y, Chen X, Liu
L, Li X, Chen J, Ma R, Guo Y, Sun P, Tian P, Pan Y, Liu Z, Cao P, Ding L, Wang
Y, Yuan X, Wu P. Befotertinib (D-0316) versus icotinib as first-line therapy for
patients with EGFR-mutated locally advanced or metastatic non-small-cell lung
cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med.
2023 Oct;11(10):905-915. doi: 10.1016/S2213-2600(23)00183-2. Epub 2023 May 24.
PMID: 37244266.
3: Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H,
Chen C, Jin X, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R,
Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y,
Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y,
Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S, Ding L, Zhang
L, Yuan X, Yao L, Shen Z. Efficacy and Safety of Befotertinib (D-0316) in
Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR
Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-
Label Study. J Thorac Oncol. 2022 Oct;17(10):1192-1204. doi:
10.1016/j.jtho.2022.06.002. Epub 2022 Jun 18. PMID: 35724798.
4: Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H,
Jin X, Chen C, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R,
Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y,
Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y,
Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S, Ding L, Zhang
L, Ji D, Shen Z. Befotertinib for patients with pretreated EGFR T790M mutated
locally advanced or metastatic NSCLC: Final overall survival results from a
phase 2 trial. Lung Cancer. 2024 Sep;195:107901. doi:
10.1016/j.lungcan.2024.107901. Epub 2024 Jul 27. PMID: 39089004.
5: Lau SCM, Ou SI. And Still They Come Over Troubled Waters: Can Asia's Third-
Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib,
Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global
Treatment of EGFR+ NSCLC. J Thorac Oncol. 2022 Oct;17(10):1144-1154. doi:
10.1016/j.jtho.2022.08.016. PMID: 36192074.
6: Menis J, Remon J. Befotertinib-a viable alternative in EGFR-mutant advanced
NSCLC? Lancet Respir Med. 2023 Oct;11(10):857-859. doi:
10.1016/S2213-2600(23)00216-3. Epub 2023 May 24. PMID: 37244264.
7: Sacchi de Camargo Correia G, Lou Y, Manochakian R. Befotertinib: one more
drug targeting EGFR-the more may be the merrier. Chin Clin Oncol. 2024 Aug
13:cco-24-50. doi: 10.21037/cco-24-50. Epub ahead of print. PMID: 39168634.
8: Zhang Z, Huang Y, Gu H, Zhao L, Zhao B. Efficacy of befotertinib in non-small
cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a
case report. Front Oncol. 2024 Apr 4;14:1370666. doi: 10.3389/fonc.2024.1370666.
PMID: 38638860; PMCID: PMC11024360.
9: Li H, Wang Y, Ding R, Chen C, Tian Z, Yin H, Ding L. Simultaneous
quantitation of befotertinib (D-0316) and its metabolite D-0865 in human plasma
by LC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jan
1;1214:123499. doi: 10.1016/j.jchromb.2022.123499. Epub 2022 Oct 17. PMID:
36525886.
10: Sørensen JB, Santoni-Rugiu E, Urbanska EM. Befotertinib in first-line
treatment for Chinese non-small cell lung cancer patients harboring common EGFR-
mutations reveals similar efficacy to other third-generation EGFR-TKIs but
somewhat different safety profile. Chin Clin Oncol. 2024 Aug 22:cco-24-19. doi:
10.21037/cco-24-19. Epub ahead of print. PMID: 39260433.
